Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 7447 |
| PDBID: | 6GWP |
| Chains: | C_A |
| Organism: | Homo sapiens, Vicugna pacos |
| Method: | XRD |
| Resolution (Å): | 2.28 |
| Reference: | 10.1111/jth.14716 |
| Antibody | |
| Antibody: | VHH-2w-64 Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Plasminogen activator inhibitor-1 (PAI-1) |
| Antigen mutation: | Yes |
| Durg Target: | P05121; P05121; |
Sequence information
Antibody
Chain: C
Mutation: NULL
| >6GWP_C|Chain C|VHH-2w-64|Vicugna pacos (30538) QVQLVESGGGLVQAGGSLRLSCAASGFTFDDYSIAWFRQAPGKEREGVSCISSSDGSAYYADSVKGRFTISSDNAKNTVYLQMNSLKPEDTAVYYCAAVWARVCRNPYDYWGQGTQVTVSS |
Antigen
Chain: A
Mutation: N150H/K154T/Q301P/Q319L/M354I
| >6GWP_A|Chain A|Plasminogen Activator Inhibitor-1|Homo sapiens (9606) VHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISHLLGTGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRPFQADFTSLSDQEPLHVALALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIIDRPFLFVVRHNPTGTVLFMGQVMEP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| C: ALA35 PHE37 GLU44 ARG45 GLU46 GLY47 VAL48 SER49 CYS50 SER52 SER54 ASP55 TYR59 TYR60 ALA61 ASP62 LYS65 ALA101 ARG102 VAL103 CYS104 ARG105 ASN106 PRO107 TYR108 A: GLU53 ASP158 LEU160 ARG162 ASP297 ARG300 PRO301 PHE302 GLN303 ALA304 ASP305 THR307 SER310 ASP311 GLN312 GLU313 PRO314 HIS316 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
